<?xml version="1.0" encoding="UTF-8"?>
<ref id="B44-marinedrugs-18-00228">
 <label>44.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Richardson</surname>
    <given-names>P.G.</given-names>
   </name>
   <name>
    <surname>Grupp</surname>
    <given-names>S.A.</given-names>
   </name>
   <name>
    <surname>Pagliuca</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Krishnan</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Ho</surname>
    <given-names>V.T.</given-names>
   </name>
   <name>
    <surname>Corbacioglu</surname>
    <given-names>S.</given-names>
   </name>
  </person-group>
  <article-title>Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure</article-title>
  <source>Intern. J. Hematol. Oncol.</source>
  <year>2017</year>
  <volume>6</volume>
  <fpage>75</fpage>
  <lpage>93</lpage>
  <pub-id pub-id-type="doi">10.2217/ijh-2017-0015</pub-id>
  <?supplied-pmid 30302228?>
  <pub-id pub-id-type="pmid">30302228</pub-id>
 </element-citation>
</ref>
